SAT-156 RENAL, CARDIOVASCULAR, AND SAFETY OUTCOMES OF CANAGLIFLOZIN ACCORDING TO BASELINE ALBUMINURIA: A CREDENCE SECONDARY ANALYSIS

Albuminuria is a strong risk factor for kidney disease progression and cardiovascular disease as reflected in the KDIGO categories of urinary ACR <30mg/g, 30-300 and >300 mg/g. The CREDENCE trial recruited participants with substantial levels of albuminuria. We examined the relative and absolute effects of canagliflozin according to baseline albuminuria among people in the CREDENCE trial.